Levetiracetam Tablet, Film Coated
Product Images NDC 76494-531

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 76494-531). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Prinston Pharmaceutical Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (9e9e646c 9d55 4222 B3ea 50f46519cf9b 02)

A formula calculating creatinine clearance (CLcr) based on age, weight, serum creatinine, and gender adjustment. It includes terms for age in years, weight in kg, serum creatinine in mg/dL, and a factor of 0.85 for female patients.*

FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (9e9e646c 9d55 4222 B3ea 50f46519cf9b 03)

A mathematical formula illustrating the calculation of creatinine clearance (CLcr) adjusted for body surface area (BSA). The formula shows CLcr in mL/min/1.73m² as the product of CLcr (mL/min) divided by the subject's BSA (m²) multiplied by 1.73.*

FDA Label Image

Levetiracetam Structural Formula (9e9e646c 9d55 4222 B3ea 50f46519cf9b 04)

Chemical structure of levetiracetam, showing the molecular framework including a pyrrolidone ring with attached ethyl side chain and amide group, consistent with its pharmaceutical identity.*

FDA Label Image

Figure 1: Responder Rate (greater Than Or Equal To 50% Reduction From Baseline) In Study 1 (9e9e646c 9d55 4222 B3ea 50f46519cf9b 05)

A bar chart titled 'Responder Rate (>50% Reduction From Baseline) In Study 1' showing percentages of patients achieving this outcome. The x-axis compares Placebo with Levetiracetam at 1000 mg/day and 3000 mg/day dosages. The y-axis represents the percentage of patients, ranging from 0% to 45%. The chart indicates responder rates of 7.4% for placebo, 37.1% for Levetiracetam 1000 mg/day, and 39.6% for Levetiracetam 3000 mg/day, with statistical significance versus placebo noted by asterisks on the Levetiracetam bars.*

FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (9e9e646c 9d55 4222 B3ea 50f46519cf9b 06)

Bar graph showing responder rates (≥50% reduction from baseline) from Study 2 Period A comparing placebo and Levetiracetam at 1000 mg/day and 2000 mg/day doses. The y-axis represents the percentage of patients, with placebo at 6.3%, Levetiracetam 1000 mg/day at 20.8%, and Levetiracetam 2000 mg/day at 35.2%. Asterisks indicate statistical significance versus placebo.*

FDA Label Image

Figure 3: Responder Rate (greater Than Or Equal To 50% Reduction From Baseline) In Study 3 (9e9e646c 9d55 4222 B3ea 50f46519cf9b 07)

A bar graph titled 'Responder Rate (≥50% Reduction From Baseline) In Study 3' compares the percentage of patients responding to placebo versus Levetiracetam 3000 mg/day. The placebo group (N=104) shows a responder rate of 14.4%, while the Levetiracetam group (N=180) shows a significantly higher responder rate of 39.4%. The graph highlights the statistical significance of Levetiracetam's efficacy compared to placebo.*

FDA Label Image

Figure 4: Responder Rate (greater Than Or Equal To 50% Reduction From Baseline) (9e9e646c 9d55 4222 B3ea 50f46519cf9b 08)

A bar graph comparing responder rates (≥50% reduction from baseline) between a placebo group (19.6%) and a Levetiracetam group (44.6%). The y-axis represents the percentage of patients, and the figure notes statistical significance versus placebo.*

FDA Label Image

Figure 6: Responder Rate (greater Than Or Equal To 50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week (9e9e646c 9d55 4222 B3ea 50f46519cf9b 10)

Bar chart comparing responder rates (≥50% reduction from baseline) in partial generalized tonic-clonic (PGTC) seizure frequency per week between placebo and Levetiracetam groups. The placebo group (N=84) shows a 45.2% responder rate, while the Levetiracetam group (N=79) shows a higher responder rate of 72.2%, marked as statistically significant versus placebo.*

FDA Label Image

Package Label-principal Display Panel (250 mg (120 Tablet Bottle))

Levetiracetam Tablets, USP 250 mg film-coated tablets label by Prinston Pharmaceutical Inc. The label includes the NDC 76494-528-12 and states the package contains 120 tablets for prescription use only. Storage instructions and manufacturer information are provided with a barcode on the right side.*

FDA Label Image

Package Label-principal Display Panel (500 mg (120 Tablet Bottle))

Levetiracetam 500 mg Tablets, USP label from Prinston Pharmaceutical Inc., containing 120 film-coated oral tablets. The label includes storage instructions, a note for pharmacists to dispense an accompanying medication guide, manufacturer details from Zhejiang Huahai Pharmaceutical Co., and a barcode.*

FDA Label Image

Package Label-principal Display Panel (750 mg (120 Tablet Bottle))

Levetiracetam 750 mg film-coated tablets label from Prinston Pharmaceutical Inc. The label shows that the package contains 120 tablets for oral use. It includes storage instructions and states that each tablet contains 750 mg of levetiracetam. The label also directs pharmacists to dispense with an accompanying Medication Guide.*

FDA Label Image

Package Label-principal Display Panel (1000 mg (60 Tablet Bottle))

Levetiracetam 1000 mg film-coated tablets label from Prinston Pharmaceutical Inc. This oral prescription drug package contains 60 tablets. The label includes storage instructions, manufacturer details, a barcode, and a note for pharmacists to dispense an accompanying Medication Guide to each patient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.